What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.
OBJECTIVE
The aim of this study was to determine the pharmacodynamics of cisplatin following three different treatment procedures for intrahepatic arterial infusion therapy for hepatocellular carcinoma (HCC).


METHODS
We divided 13 HCC patients into the following three groups: group A, lone injection of cisplatin (n=3); group B, combined injection of cisplatin and lipiodol, with embolization using small gelatin cubes (GCs) (n=5); and group C, injection of suspended lipiodol with cisplatin powder, with embolization using small GCs (n=5). In each group, the free cisplatin concentration in the hepatic vein was measured at 0, 5, 10, and 30 minutes.


RESULTS
The mean free cisplatin concentrations were as follows. For group A, the mean was 48.58 µg/mL at 0 minute, 7.31 µg/mL at 5 minutes, 5.70 µg/mL at 10 minutes, and 7.15 µg/mL at 30 minutes. For the same time points, for group B, the concentrations were 8.66, 4.23, 3.22, and 1.65 µg/mL, respectively, and for group C, the concentrations were 4.81, 2.61, 2.52, and 1.75 µg/mL, respectively. The mean area under the curve (AUC)0-infinity for the free cisplatin concentration was 7.80 in group A, 2.48 in group B, and 2.27 in group C. The AUC0-infinity for the free cisplatin concentration gradually decreased, from group A to group C.


CONCLUSIONS
These results indicate that the combination of lipiodol and small GCs may be useful for delaying cisplatin drainage from the liver.
Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
Yusuke
Y
Kawamura
Kenji
K
Ikeda
Taito
T
Fukushima
Yuya
Y
Seko
Tasuku
T
Hara
Hitomi
H
Sezaki
Tetsuya
T
Hosaka
Norio
N
Akuta
Masahiro
M
Kobayashi
Satoshi
S
Saitoh
Fumitaka
F
Suzuki
Yoshiyuki
Y
Suzuki
Yasuji
Y
Arase
Hiromitsu
H
Kumada
Attention; Carcinoma, hepatocellular; Cisplatin; Drug delivery